Results 231 to 240 of about 378,593 (354)

Inhibition of Ferroptosis Delays Aging and Extends Healthspan Across Multiple Species

open access: yesAdvanced Science, EarlyView.
This study identifies ferroptosis as a key driver of cellular senescence, with its inhibition delaying aging and extending healthspan across species. During senescence, ferroptosis worsens, increasing oxidative stress and lipid peroxidation, which accelerate aging.
Hai‐Jun Fu   +15 more
wiley   +1 more source

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

open access: yesAmerican Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon   +25 more
wiley   +1 more source

Biomimetic MOF Nanocarrier‐Mediated Synergistic Delivery of Mitochondria and Anti‐Inflammatory miRNA to Alleviate Acute Lung Injury

open access: yesAdvanced Science, EarlyView.
A biomimetic MOF nanocarrier for macrophage‐targeting delivery of both mitochondria and anti‐miR‐127 is designed with an aim to revitalize macrophages and remold the inflammatory microenvironment for treating acute lung injury. By leveraging the macrophages‐targeting property and pH‐responsiveness, ZIF‐8 nanocarriers facilitated efficient delivery of ...
Xin Shou   +10 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

open access: yesAmerican Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan   +18 more
wiley   +1 more source

Reversible High‐Affinity Binding of Coagulation Factor Xa to Zeolites Induces Accelerated Blood Coagulation

open access: yesAdvanced Science, EarlyView.
A calcium‐dependent, specific biorecognition between coagulation factor Xa (FXa) and zeolite is discovered. It alters the prothrombin activation pathway to a more efficient mechanism by mimicking the FXa/factor Va (FXa/FVa) interaction formed during the natural coagulation cascade.
Chaojie Shi   +9 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

open access: yesAmerican Journal of Hematology, Volume 98, Issue 2, Page 338-347, February 2023., 2023
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy